Why ARESTIN?

ARESTIN (minocycline HCl) Microspheres, 1 mg is a concentrated, locally applied antibiotic that remains active in the pocket for an extended period of time to reduce pocket depth.1 The microspheres release antibiotic over time, targeting bacteria to reduce pocket depth, so gums can heal better than with scaling and root planing (SRP) alone.2


When incorporated into a routine oral maintenance program along with SRP, ARESTIN:

  • Targeted periodontal bacteria to fight infection at 1 month.3*
  • Provided significantly greater pocket depth reduction for up to 3 months vs SRP alone.1†
  • Resulted in reduced pocket depth after 1 month and maintained at 9 months.2†

See additional study data


Without an antibiotic such as ARESTIN, baseline levels of bacteria may return in just a few days, even after SRP.4

The effects of ARESTIN on microorganism overgrowth have not been studied beyond 6 months.


Fight infection by going deep

In a clinical study, ARESTIN + SRP reduced harmful bacteria by nearly 2x as much as SRP alone.3,5,6* Adding ARESTIN to SRP disrupts the pathogenic progression of periodontitis by specifically targeting the active infection.2


ARESTIN + SRP reduced pocket depth more effectively 
than SRP alone, even in the most susceptible patients2

WATCH THIS VIDEO

to see the role of ARESTIN in periodontal treatment.

Help your patients save on ARESTIN treatment.

Learn more

*Single-blind, randomized, parallel-group study of 127 patients with moderate-to-severe periodontitis who had at least 5 teeth with ≥5 mm pocket depths. Mean RCB numbers at day 30 were reduced from 18.9 x 105 to 9.50 x 105 (50%) by ARESTIN + SRP (p=0.002) and from 19.3 x 105 to 14.2 x 105 (26%) by SRP alone (p=0.002).

†In 2 multicenter, investigator-blind, parallel-design studies of 748 patients with generalized moderate to advanced adult periodontitis characterized by a mean probing depth of 5.90 and 5.81 mm, subjects received 1 of 3 treatments: (1) SRP, (2) SRP + vehicle, and (3) SRP + ARESTIN. Retreatment occurred at 3 and 6 months after initial treatment, and any new site with pocket depth ≥5 mm also received treatment. Patients treated with ARESTIN were found to have statistically significantly reduced probing pocket depth compared with those treated with SRP alone or SRP + vehicle at 9 months after initial treatment. ARESTIN vs SRP alone (n=250) p<0.01; ARESTIN vs vehicle + SRP (n=249) p<0.001; ARESTIN + SRP vs vehicle (n=249) p<0.001.

‡Subpopulation (n=101) of combined, single-blind, Phase III trial comparing ARESTIN + SRP to SRP alone and SRP + placebo (n=748). SRP was performed for all groups at baseline. ARESTIN or vehicle was administered to periodontal pockets ≥5 mm in the adjunctive therapy groups at baseline, 3 months, and 6 months. Efficacy was evaluated over 9 months. At 9 months, ARESTIN + SRP had a 58% greater therapeutic effect vs. SRP alone in periodontal patients with cardiovascular disease (P≤0.001). 

§Subpopulation (n=271) of combined, single-blind, Phase III trials comparing ARESTIN + SRP to SRP alone and SRP + placebo (n=748). SRP was performed for all groups at baseline. ARESTIN or vehicle was administered to periodontal pockets ≥5 mm in the adjunctive therapy groups at baseline, 3 months, and 6 months. Efficacy was evaluated over 9 months. At 9 months, ARESTIN + SRP had a 29% greater therapeutic effect vs. SRP alone in smokers (P≤0.001). 

||Subpopulation (n=109) of combined, single-blind, Phase III trial comparing ARESTIN + SRP to SRP alone and SRP + placebo (n=748). SRP was performed for all groups at baseline. ARESTIN or vehicle was administered to periodontal pockets ≥5 mm in the adjunctive therapy groups at baseline, 3 months, and 6 months. Efficacy was evaluated over 9 months. At 9 months, ARESTIN + SRP had a 33% greater therapeutic effect vs. SRP alone in patients over the age of 50 (P≤0.001). 

REFERENCES: 1. Williams RC, Paquette DW, Offenbacher S, et al. Treatment of periodontitis by local administration of minocycline microspheres: a controlled trial. J Periodontol. 2001;72(11):1535-1544. 2. ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg. Prescribing Information. OraPharma; Horsham PA: 2015. 3. Goodson JM, Gunsolley JC, Grossi SG, et al. Minocycline HCl microspheres reduce red-complex bacteria in periodontal disease therapy. J Periodontol. 2007;78(8):1568-1579. 4. Socransky SS, Haffajee AD. Dental biofilms: difficult therapeutic targets. Periodontol 2000. 2002;28:12-55. 5. Doherty F, Lessem J, Hanlon A, Rose T. Efficacy of Arestin in perio maintenance patients. J Clin Periodontol. 2003;30(suppl 4):19-100. 6. Grossi SG, Goodson JM, Gunsolley JC, et al. Mechanical therapy with adjunctive minocycline microspheres reduces red-complex bacteria in smokers. J Periodontol. 2007;78(9):1741-1750.